Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease

Nature Reviews Drug Discovery

Volumn 15, Issue 9, 2016, Pages 620-638

  Gourdie, Robert G ^a,b,c   Dimmeler, Stefanie ^d,e   Kohl, Peter ^f,g,h  

^a VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c Carilion Clinic   (United States)

^d GOETHE UNIVERSITY   (Germany)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^f UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; BATIMASTAT; BOSENTAN; ENALAPRIL; LOSARTAN; NEDOCROMIL; PROPRANOLOL; SERELAXIN; SPIRONOLACTONE;

DRUG MECHANISM; HEART DEVELOPMENT; HEART DISEASE; HEART FAILURE; HEART FIBROBLAST; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYPERTENSION; MESENCHYME CELL; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCAR FORMATION; STEM CELL TRANSPLANTATION; TISSUE REPAIR; ANIMAL; DRUG EFFECTS; FIBROBLAST; FIBROSIS; HEART DISEASES; PATHOLOGY;

ANIMALS; FIBROBLASTS; FIBROSIS; HEART DISEASES; HEART FAILURE; HUMANS;

EID: 84955612078     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2016.89     Document Type: Review

References (308)

1. Porter, K. E., & Turner, N. A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Ther. 123, 255-278 (2009
2. Kohl, P., & Gourdie, R. G. Fibroblast-myocyte electrotonic coupling: does it occur in native cardiac tissue? J. Mol. Cell. Cardiol. 70, 37-46 (2014
3. Kong, P., Christia, P., & Frangogiannis, N. G. The pathogenesis of cardiac fibrosis. Cell. Mol. Life Sci. 71, 549-574 (2014
4. Moore-Morris, T., Guimaraes-Camboa, N., Yutzey, K. E., Puceat, M., & Evans, S. M. Cardiac fibroblasts: from development to heart failure. J. Mol. Med. (Berl.) 93, 823-830 (2015
5. Davis, J., & Molkentin, J. D. Myofibroblasts: trust your heart and let fate decide. J. Mol. Cell. Cardiol. 70, 9-18 (2014
6. Leask, A. Getting to the heart of the matter: new insights into cardiac fibrosis. Circ. Res. 116, 1269-1276 (2015
7. Vasquez, C., & Morley, G. E. The origin and arrhythmogenic potential of fibroblasts in cardiac disease. J. Cardiovasc. Transl. Res. 5, 760-767 (2012
8. Ongstad, E. L., & Gourdie, R. G. Myocyte-fibroblast electrical coupling: the basis of a stable relationship? Cardiovascular Res. 93, 215-217 (2012
9. Mozaffarian, D., et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 131, e29-e322 (2015
10. Spinale, F. G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 87, 1285-1342 (2007
11. Caulfield, J. B., & Borg, T. K. The collagen network of the heart. Lab. Invest. 40, 364-371 (1979
12. Hales, P. W., et al. Histo-Anatomical structure of the living isolated rat heart in two contraction states assessed by diffusion tensor MRI. Prog. Biophys. Mol. Biol. 110, 319-330 (2012
13. Ott, H. C., et al. Perfusion-decellularized matrix: using nature?s platform to engineer a bioartificial heart. Nat. Med. 14, 213-221 (2008
14. Sanchez, P. L., et al. Acellular human heart matrix: a critical step toward whole heart grafts. Biomaterials 61, 279-289 (2015
15. Lu, T. Y., et al. Repopulation of decellularized mouse heart with human induced pluripotent stem cell-derived cardiovascular progenitor cells. Nat. Commun. 4, 2307 (2013
16. Tedder, M. E., et al. Stabilized collagen scaffolds for heart valve tissue engineering. Tissue Eng. Part A 15, 1257-1268 (2009
17. Yacoub, M. H. In search of living valve substitutes. J. Am. Coll. Cardiol. 66, 889-891 (2015
18. Mohamed, T. M. A., et al. The plasma membrane calcium ATPase 4 signalling in cardiac fibroblasts mediates cardiomyocyte hypertrophy. Nat. Commun. 7, 11074 (2016
19. De Maziere, A. M., van Ginneken, A. C., Wilders, R., Jongsma, H. J., & Bouman, L. N. Spatial and functional relationship between myocytes and fibroblasts in the rabbit sinoatrial node. J. Mol. Cell. Cardiol. 24, 567-578 (1992
20. Camelliti, P., Green, C. R., LeGrice, I., & Kohl, P. Fibroblast network in rabbit sinoatrial node: structural and functional identification of homogeneous and heterogeneous cell coupling. Circ. Res. 94, 828-835 (2004
21. Vasquez, C., et al. Enhanced fibroblast-myocyte interactions in response to cardiac injury. Circ. Res. 107, 1011-1020 (2010
22. Nguyen, T. P., Xie, Y., Garfinkel, A., Qu, Z., & Weiss, J. N. Arrhythmogenic consequences of myofibroblast-myocyte coupling. Cardiovasc. Res. 93, 242-251 (2012
23. Nisbet, A. M., et al. Prolongation of atrio-ventricular node conduction in a rabbit model of ischaemic cardiomyopathy: role of fibrosis and connexin remodelling. J. Mol. Cell. Cardiol. 94, 54-64 (2016
24. Hiruma, T., & Hirakow, R. Epicardial formation in embryonic chick heart: computer-Aided reconstruction, scanning, and transmission electron microscopic studies. Am. J. Anat. 184, 129-138 (1989
25. Mikawa, T., & Gourdie, R. G. Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial organ. Dev. Biol. 174, 221-232 (1996
26. Manasek, F. J. Embryonic development of the heart. II. Formation of the epicardium. J. Embryol. Exp. Morphol. 22, 333-348 (1969
27. Dettman, R. W., Denetclaw, W. Jr, Ordahl, C. P., & Bristow, J. Common epicardial origin of coronary vascular smooth muscle, perivascular fibroblasts, and intermyocardial fibroblasts in the avian heart. Dev. Biol. 193, 169-181 (1998
28. Gittenberger de Groot, A. C., Vrancken Peeters, M. P., Mentink, M. M., Gourdie, R. G., & Poelmann, R. E. Epicardium-derived cells contribute a novel population to the myocardial wall and the atrioventricular cushions. Circul. Res. 82, 1043-1052 (1998
29. Mizutani, M., Wu, J. C., & Nusse, R. Fibrosis of the neonatal mouse heart after cryoinjury is accompanied by Wnt signaling activation and epicardial-To mesenchymal transition. J. Am. Heart Assoc. 4, e002457 (2016
30. Cano, E., Carmona, R., Velecela, V., Martinez-Estrada, O., & Munoz-Chapuli, R. The proepicardium keeps a potential for glomerular marker expression which supports its evolutionary origin from the pronephros. Evol. Dev. 17, 224-230 (2015
31. Schlueter, J., Manner, J., & Brand, T. BMP is an important regulator of proepicardial identity in the chick embryo. Dev. Biol. 295, 546-558 (2006
32. Merki, E., et al. Epicardial retinoid X receptor α is required for myocardial growth and coronary artery formation. Proc. Natl Acad. Sci. USA 102, 18455-18460 (2005
33. Compton, L. A., Potash, D. A., Mundell, N. A., & Barnett, J. V. Transforming growth factor-β induces loss of epithelial character and smooth muscle cell differentiation in epicardial cells. Dev. Dyn. 235, 82-93 (2006
34. Martinez-Estrada, O. M., et al. Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E cadherin. Nat. Genet. 42, 89-93 (2010
35. Wu, S. P., Dong, X. R., Regan, J. N., Su, C., & Majesky, M. W. Tbx18 regulates development of the epicardium and coronary vessels. Dev. Biol. 383, 307-320 (2013
36. Furtado, M. B., et al. Cardiogenic genes expressed in cardiac fibroblasts contribute to heart development and repair. Circ. Res. 114, 1422-1434 (2014
37. Sanchez, N. S., & Barnett, J. V. TGFβ and BMP 2 regulate epicardial cell invasion via TGFβR3 activation of the Par6/Smurf1/RhoA pathway. Cell Signal. 24, 539-548 (2012
38. Allison, P., Espiritu, D., Barnett, J. V., & Camenisch, T. D. Type III TGFβ receptor and Src direct hyaluronan-mediated invasive cell motility. Cell Signal. 27, 453-459 (2015
39. Vega-Hernandez, M., Kovacs, A., De Langhe, S., & Ornitz, D. M. FGF10/FGFR2b signaling is essential for cardiac fibroblast development and growth of the myocardium. Development 138, 3331-3340 (2011
40. Smith, C. L., Baek, S. T., Sung, C. Y., & Tallquist, M. D. Epicardial-derived cell epithelial-To mesenchymal transition and fate specification require PDGF receptor signaling. Circ. Res. 108, e15-e26 (2011
41. Artamonov, M. V., et al. Signaling pathways that control rho kinase activity maintain the embryonic epicardial progenitor state. J. Biol. Chem. 290, 10353-10367 (2015
42. Dettman, R. W., Pae, S. H., Morabito, C., & Bristow, J. Inhibition of α4 integrin stimulates epicardial-mesenchymal transformation and alters migration and cell fate of epicardially derived mesenchyme. Dev. Biol. 257, 315-328 (2003
43. Benesh, E. C., et al. Bves and NDRG4 regulate directional epicardial cell migration through autocrine extracellular matrix deposition. Mol. Biol. Cell 24, 3496-3510 (2013
44. Brand, T., Simrick, S. L., Poon, K. L., & Schindler, R. F. The cAMP-binding Popdc proteins have a redundant function in the heart. Biochem. Soc. Trans. 42, 295-301 (2014
45. Landerholm, T. E., et al. A role for serum response factor in coronary smooth muscle differentiation from proepicardial cells. Development 126, 2053-2062 (1999
46. Acharya, A., et al. The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors. Development 139, 2139-2149 (2012
47. Tandon, P., Miteva, Y. V., Kuchenbrod, L. M., Cristea, I. M., & Conlon, F. L. Tcf21 regulates the specification and maturation of proepicardial cells. Development 140, 2409-2421 (2013
48. Trembley, M. A., Velasquez, L. S., de Mesy Bentley, K. L., & Small, E. M. Myocardin-related transcription factors control the motility of epicardium-derived cells and the maturation of coronary vessels. Development 142, 21-30 (2015
49. Bouacida, A., et al. Pericyte-like progenitors show high immaturity and engraftment potential as compared with mesenchymal stem cells. PLoS ONE 7, e48648 (2012
50. Volz, K. S., et al. Pericytes are progenitors for coronary artery smooth muscle. eLife 4, e10036 (2015
51. Birbrair, A., et al. Type 1 pericytes accumulate after tissue injury and produce collagen in an organ-dependent manner. Stem Cell Res. Ther. 5, 122 (2014
52. Eisenberg, L. M., & Markwald, R. R. Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circul. Res. 77, 1-6 (1995
53. Hutson, M. R., & Kirby, M. L. Neural crest and cardiovascular development: a 20 year perspective. Birth Defects Res. C Embryo Today 69, 2-13 (2003
54. Rentschler, S., Jain, R., & Epstein, J. A. Tissue-Tissue interactions during morphogenesis of the outflow tract. Pediatr. Cardiol. 31, 408-413 (2010
55. Ali, S. R., et al. Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circ. Res. 115, 625-635 (2014
56. Cheng, G., et al. Development of the cardiac conduction system involves recruitment within a multipotent cardiomyogenic lineage. Development 126, 5041-5049 (1999
57. Nakajima, Y., Mironov, V., Yamagishi, T., Nakamura, H., & Markwald, R. R. Expression of smooth muscle alpha-Actin in mesenchymal cells during formation of avian endocardial cushion tissue: a role for transforming growth factor β3. Dev. Dyn. 209, 296-309 (1997
58. Martin, P., Tzanidis, A., Stein-Oakley, A., & Krum, H. Effect of a highly selective endothelin-converting enzyme inhibitor on cardiac remodeling in rats after myocardial infarction. J. Cardiovasc. Pharmacol. 36, S367-S370 (2000
59. Campbell, S. E., & Katwa, L. C. Angiotensin II stimulated expression of transforming growth factor β1 in cardiac fibroblasts and myofibroblasts. J. Mol. Cell. Cardiol. 29, 1947-1958 (1997
60. Dai, P., Nakagami, T., Tanaka, H., Hitomi, T., & Takamatsu, T. Cx43 mediates TGF-β signaling through competitive Smads binding to microtubules. Mol. Biol. Cell 18, 2264-2273 (2007
61. Asazuma-Nakamura, Y., et al. Cx43 contributes to TGF-β signaling to regulate differentiation of cardiac fibroblasts into myofibroblasts. Exp. Cell Res. 315, 1190-1199 (2009
62. Sanders, Y. Y., et al. SMAD-independent down-regulation of caveolin 1 by TGF-β: effects on proliferation and survival of myofibroblasts. PLoS ONE 10, e0116995 (2015
63. Xia, Y., et al. Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism. Hypertension 58, 902-911 (2011
64. McCurdy, S., Baicu, C. F., Heymans, S., & Bradshaw, A. D. Cardiac extracellular matrix remodeling: fibrillar collagens and secreted protein acidic and rich in cysteine (SPARC). J. Mol. Cell. Cardiol. 48, 544-549 (2010
65. Oka, T., et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ. Res. 101, 313-321 (2007
66. Nishioka, T., et al. Eplerenone attenuates myocardial fibrosis in the angiotensin II induced hypertensive mouse: involvement of tenascin C induced by aldosterone-mediated inflammation. J. Cardiovasc. Pharmacol. 49, 261-268 (2007
67. Grotendorst, G. R., & Duncan, M. R. Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J. 19, 729-738 (2005
68. Dubash, A. D., et al. Plakophilin 2 loss promotes TGF β1/p38 MAPK-dependent fibrotic gene expression in cardiomyocytes. J. Cell Biol. 212, 425-438 (2016
69. Jeong, D., et al. Matricellular protein CCN5 reverses established cardiac fibrosis. J. Am. Coll. Cardiol. 67, 1556-1568 (2016
70. Kaur, H., et al. Targeted ablation of periostin-expressing activated fibroblasts prevents adverse cardiac remodeling in mice. Circ. Res. http://dx.doi.org/10.1161/CIRCRESAHA.116.308643 (2016
71. Blaauw, E., et al. Stretch-induced upregulation of connective tissue growth factor in rabbit cardiomyocytes. J. Cardiovasc. Transl. Res. 6, 861-869 (2013
72. Fomovsky, G. M., Rouillard, A. D., & Holmes, J. W. Regional mechanics determine collagen fiber structure in healing myocardial infarcts. J. Mol. Cell. Cardiol. 52, 1083-1090 (2012
73. Dalla Costa, A. P., et al. FAK mediates the activation of cardiac fibroblasts induced by mechanical stress through regulation of the mTOR complex. Cardiovasc. Res. 86, 421-431 (2010
74. Kamkin, A., Kiseleva, I., & Isenberg, G. Activation and inactivation of a non-selective cation conductance by local mechanical deformation of acutely isolated cardiac fibroblasts. Cardiovasc. Res. 57, 793-803 (2003
75. Kiseleva, I., Kamkin, A., Kohl, P., & Lab, M. J. Calcium and mechanically induced potentials in fibroblasts of rat atrium. Cardiovasc. Res. 32, 98-111 (1996
76. Peyronnet, R., Nerbonne, J. M., & Kohl, P. Cardiac mechano-gated ion channels and arrhythmias. Circ. Res. 118, 311-329 (2016
77. van den Borne, S. W., et al. Myocardial remodeling after infarction: the role of myofibroblasts. Nat. Rev. Cardiol. 7, 30-37 (2010
78. Roche, P. L., Filomeno, K. L., Bagchi, R. A., & Czubryt, M. P. Intracellular signaling of cardiac fibroblasts. Compr. Physiol. 5, 721-760 (2015
79. Nakatsuji, S., Yamate, J., Kuwamura, M., Kotani, T., & Sakuma, S. In vivo responses of macrophages and myofibroblasts in the healing following isoproterenol-induced myocardial injury in rats. Virchows Arch. 430, 63-69 (1997
80. Shiraishi, M., et al. Alternatively activated macrophages determine repair of the infarcted adult murine heart. J. Clin. Invest. http://dx.doi.org/10.1172/JCI85782 (2016
81. Willems, I. E., Havenith, M. G., De Mey, J. G., & Daemen, M. J. The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am. J. Pathol. 145, 868-875 (1994
82. Hulsmans, M., Sam, F., & Nahrendorf, M. Monocyte and macrophage contributions to cardiac remodeling. J. Mol. Cell. Cardiol. 93, 149-155 (2016
83. van den Borne, S. W., et al. Mouse strain determines the outcome of wound healing after myocardial infarction. Cardiovasc. Res. 84, 273-282 (2009
84. Kong, P., Christia, P., Saxena, A., Su, Y., & Frangogiannis, N. G. Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis. Am. J. Physiol. Heart Circ. Physiol. 305, H1363-H1372 (2013
85. Zhou, B., von Gise, A., Ma, Q., Hu, Y. W., & Pu, W. T. Genetic fate mapping demonstrates contribution of epicardium-derived cells to the annulus fibrosis of the mammalian heart. Dev. Biol. 338, 251-261 (2010
86. Moore-Morris, T., et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J. Clin. Invest. 124, 2921-2934 (2014
87. Ruiz-Villalba, A., et al. Interacting resident epicardium-derived fibroblasts and recruited bone marrow cells form myocardial infarction scar. J. Am. Coll. Cardiol. 65, 2057-2066 (2015
88. Mollmann, H., et al. Bone marrow-derived cells contribute to infarct remodelling. Cardiovasc. Res. 71, 661-671 (2006
89. Visconti, R. P., & Markwald, R. R. Recruitment of new cells into the postnatal heart: potential modification of phenotype by periostin. Ann. NY Acad. Sci. 1080, 19-33 (2006
90. Crawford, J. R., Haudek, S. B., Cieslik, K. A., Trial, J., & Entman, M. L. Origin of developmental precursors dictates the pathophysiologic role of cardiac fibroblasts. J. Cardiovasc. Transl. Res. 5, 749-759 (2012
91. Cieslik, K. A., Trial, J., Crawford, J. R., Taffet, G. E., & Entman, M. L. Adverse fibrosis in the aging heart depends on signaling between myeloid and mesenchymal cells; role of inflammatory fibroblasts. J. Mol. Cell. Cardiol. 70, 56-63 (2014
92. Duerrschmid, C., Trial, J., Wang, Y., Entman, M. L., & Haudek, S. B. Tumor necrosis factor: a mechanistic link between angiotensin-II induced cardiac inflammation and fibrosis. Circ. Heart Fail. 8, 352-361 (2015
93. Zeisberg, E. M., et al. Endothelial-To mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13, 952-961 (2007
94. Deb, A., & Ubil, E. Cardiac fibroblast in development and wound healing. J. Mol. Cell. Cardiol. 70, 47-55 (2014
95. Ongstad, E., & Kohl, P. Fibroblast-myocyte coupling in the heart: potential relevance for therapeutic interventions. J. Mol. Cell. Cardiol. 91, 238-246 (2016
96. Kikuchi, K., & Poss, K. D. Cardiac regenerative capacity and mechanisms. Annu. Rev. Cell Dev. Biol. 28, 719-741 (2012
97. Gerbin, K. A., & Murry, C. E. The winding road to regenerating the human heart. Cardiovasc. Pathol. 24, 133-140 (2015
98. Porrello, E. R., et al. Transient regenerative potential of the neonatal mouse heart. Science 331, 1078-1080 (2011
99. Nakada, Y., Kimura, W., & Sadek, H. A. Defining the limit of embryonic heart regeneration. Circulation 132, 77-78 (2015
100. Takahashi, K., & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006
101. Sadahiro, T., Yamanaka, S., & Ieda, M. Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications. Circ. Res. 116, 1378-1391 (2015
102. Ieda, M., et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142, 375-386 (2010
103. Qian, L., et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 485, 593-598 (2012
104. Song, K., et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 485, 599-604 (2012
105. Jayawardena, T. M., et al. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ. Res. 110, 1465-1473 (2012
106. Smart, N., et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature 474, 640-644 (2011
107. Gajzer, D. C., Balbin, J., & Chaudhry, H. W. Thymosin β4 and cardiac regeneration: are we missing a beat? Stem Cell Rev. 9, 303-312 (2013
108. Chen, J. X., et al. Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circ. Res. 111, 50-55 (2012
109. Wang, L., et al. Stoichiometry of Gata4, Mef2c, and Tbx5 influences the efficiency and quality of induced cardiac myocyte reprogramming. Circ. Res. 116, 237-244 (2015
110. Nam, Y. J., et al. Reprogramming of human fibroblasts toward a cardiac fate. Proc. Natl Acad. Sci. USA 110, 5588-5593 (2013
111. Muraoka, N., et al. MiR 133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures. EMBO J. 33, 1565-1581 (2014
112. Pratico, E. D., et al. RNA-mediated reprogramming of primary adult human dermal fibroblasts into c kit+ cardiac progenitor cells. Stem Cells Dev. 24, 2622-2633 (2015
113. Nam, Y. J., et al. Induction of diverse cardiac cell types by reprogramming fibroblasts with cardiac transcription factors. Development 141, 4267-4278 (2014
114. Ifkovits, J. L., Addis, R. C., Epstein, J. A., & Gearhart, J. D. Inhibition of TGFβ signaling increases direct conversion of fibroblasts to induced cardiomyocytes. PLoS ONE 9, e89678 (2014
115. Zhou, H., Dickson, M. E., Kim, M. S., Bassel-Duby, R., & Olson, E. N. Akt1/protein kinase B enhances transcriptional reprogramming of fibroblasts to functional cardiomyocytes. Proc. Natl Acad. Sci. USA 112, 11864-11869 (2015
116. Towbin, J. A. Scarring in the heart-A reversible phenomenon? N. Engl. J. Med. 357, 1767-1768 (2007
117. Gulati, A., et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309, 896-908 (2013
118. Klem, I., et al. Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J. Am. Coll. Cardiol. 60, 408-420 (2012
119. Esposito, G., Dellegrottaglie, S., & Chiariello, M. The extent of irreversible myocardial damage and the potential for left ventricular repair after primary percutaneous coronary intervention. Am. Heart J. 160, S4-S10 (2010
120. Vander Heide, R. S., & Steenbergen, C. Cardioprotection and myocardial reperfusion: pitfalls to clinical application. Circ. Res. 113, 464-477 (2013
121. Murry, C. E., Jennings, R. B., & Reimer, K. A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74, 1124-1136 (1986
122. Fordyce, C. B., Gersh, B. J., Stone, G. W., & Granger, C. B. Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury. Trends Pharmacol. Sci. 36, 605-615 (2015
123. Jones, S. P., et al. The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. Circ. Res. 116, 572-586 (2015
124. Heusch, G., Botker, H. E., Przyklenk, K., Redington, A., & Yellon, D. Remote ischemic conditioning. J. Am. Coll. Cardiol. 65, 177-195 (2015
125. Hausenloy, D. J., & Yellon, D. M. Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis 204, 334-341 (2009
126. Duncker, D. J., & Verdouw, P. D. Role of K+ATP channels in ischemic preconditioning and cardioprotection. Cardiovasc. Drugs Ther. 14, 7-16 (2000
127. Chen, C. H., et al. Activation of aldehyde dehydrogenase 2 reduces ischemic damage to the heart. Science 321, 1493-1495 (2008
128. Kornfeld, O. S., et al. Mitochondrial reactive oxygen species at the heart of the matter: new therapeutic approaches for cardiovascular diseases. Circ. Res. 116, 1783-1799 (2015
129. Monassier, L., Ayme-Dietrich, E., Aubertin-Kirch, G., & Pathak, A. Targeting myocardial reperfusion injuries with cyclosporine in the CIRCUS Trial-pharmacological reasons for failure. Fundam. Clin. Pharmacol. 30, 191-193 (2015
130. Das, A., Durrant, D., Salloum, F. N., Xi, L., & Kukreja, R. C. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol. Ther. 147, 12-21 (2015
131. Adkins, G. B., & Curtis, M. J. Potential role of cardiac chloride channels and transporters as novel therapeutic targets. Pharmacol. Ther. 145, 67-75 (2015
132. Shen, Y., Shen, Z., Luo, S., Guo, W., & Zhu, Y. Z. The cardioprotective effects of hydrogen sulfide in heart diseases: from molecular mechanisms to therapeutic potential. Oxid. Med. Cell. Longev. 2015, 925167 (2015
133. Das, A., et al. Inhibition of mammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling. Bas. Res. Cardiol. 110, 31 (2015
134. Sun, J., & Murphy, E. Protein S nitrosylation and cardioprotection. Circ. Res. 106, 285-296 (2010
135. Luo, J., Obal, D., Dimova, N., Tang, X. L., & Rokosh, G. Cardiac myocyte-specific transgenic ecSOD targets mitochondria to protect against Ca2+ induced permeability transition. Front. Physiol. 4, 295 (2013
136. Hawat, G., Helie, P., & Baroudi, G. Single intravenous low-dose injections of connexin 43 mimetic peptides protect ischemic heart in vivo against myocardial infarction. J. Mol. Cell. Cardiol. 53, 559-566 (2012
137. Wang, N., et al. Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Bas. Res. Cardiol. 108, 309 (2013
138. Rhett, J. M., Jourdan, J., & Gourdie, R. G. Connexin 43 connexon to gap junction transition is regulated by zonula occludens 1. Mol. Biol. Cell 22, 1516-1528 (2011
139. Sluijter, J. P., et al. Novel therapeutic strategies for cardioprotection. Pharmacol. Ther. 144, 60-70 (2014
140. Desplantez, T., Verma, V., Leybaert, L., Evans, W. H., & Weingart, R. Gap26, a connexin mimetic peptide, inhibits currents carried by connexin43 hemichannels and gap junction channels. Pharmacol. Res. 65, 546-552 (2012
141. Davidson, J. O., Green, C. R., Bennet, L., & Gunn, A. J. Battle of the hemichannels-connexins and pannexins in ischemic brain injury. Int. J. Dev. Neurosci. 45, 66-74 (2014
142. Afzal, M. R., et al. Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circ. Res. 117, 558-575 (2015
143. Karantalis, V., & Hare, J. M. Use of mesenchymal stem cells for therapy of cardiac disease. Circ. Res. 116, 1413-1430 (2015
144. Delewi, R., et al. Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST segment elevation myocardial infarction: a collaborative meta-Analysis. Eur. Heart J. 35, 989-998 (2014
145. Assmus, B., Dimmeler, S., & Zeiher, A. M. Cardiac cell therapy: lost in meta-Analyses. Circ. Res. 116, 1291-1292 (2015
146. Gyongyosi, M., et al. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ. Res. 116, 1346-1360 (2015
147. Leri, A., Rota, M., Pasqualini, F. S., Goichberg, P., & Anversa, P. Origin of cardiomyocytes in the adult heart. Circ. Res. 116, 150-166 (2015
148. Bolli, R., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378, 1847-1857 (2011
149. Makkar, R. R., et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised Phase 1 trial. Lancet 379, 895-904 (2012
150. Bergmann, O., et al. Evidence for cardiomyocyte renewal in humans. Science 324, 98-102 (2009
151. Ellison, G. M., et al. Adult c kitpos cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell 154, 827-842 (2013
152. van Berlo, J. H., et al. c kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509, 337-341 (2014
153. Zaruba, M. M., Soonpaa, M., Reuter, S., & Field, L. J. Cardiomyogenic potential of c kit+-expressing cells derived from neonatal and adult mouse hearts. Circulation 121, 1992-2000 (2010
154. Sultana, N., et al. Resident c kit+ cells in the heart are not cardiac stem cells. Nat. Commun. 6, 8701 (2015
155. Liu, Q., et al. Genetic lineage tracing identifies in situ Kit-expressing cardiomyocytes. Cell Res. 26, 119-130 (2016
156. Uchida, S., et al. Sca1 derived cells are a source of myocardial renewal in the murine adult heart. Stem Cell Rep. 1, 397-410 (2013
157. Abbott, A. Doubts over heart stem-cell therapy. Nature 509, 15-16 (2014
158. Burchfield, J. S., & Dimmeler, S. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogen. Tissue Repair 1, 4 (2008
159. Kinnaird, T., et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ. Res. 94, 678-685 (2004
160. Pak, H. N., et al. Mesenchymal stem cell injection induces cardiac nerve sprouting and increased tenascin expression in a Swine model of myocardial infarction. J. Cardiovasc. Electrophysiol. 14, 841-848 (2003
161. Seeger, F. H., et al. CXCR4 expression determines functional activity of bone marrow-derived mononuclear cells for therapeutic neovascularization in acute ischemia. Arterioscler. Thromb. Vasc. Biol. 29, 1802-1809 (2009
162. Li, L., et al. Paracrine action mediate the antifibrotic effect of transplanted mesenchymal stem cells in a rat model of global heart failure. Mol. Biol. Rep. 36, 725-731 (2009
163. Gnecchi, M., et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 20, 661-669 (2006
164. Li, Z., Wei, H., Deng, L., Cong, X., & Chen, X. Expression and secretion of interleukin 1β, tumour necrosis factor-α and interleukin 10 by hypoxia-And serum-deprivation-stimulated mesenchymal stem cells. FEBS J. 277, 3688-3698 (2010
165. Chen, P., et al. Hypoxia preconditioned mesenchymal stem cells prevent cardiac fibroblast activation and collagen production via leptin. PLoS ONE 9, e103587 (2014
166. Korf-Klingebiel, M., et al. Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. Nat. Med. 21, 140-149 (2015
167. Sahoo, S., & Losordo, D. W. Exosomes and cardiac repair after myocardial infarction. Circ. Res. 114, 333-344 (2014
168. Malliaras, K., et al. Stimulation of endogenous cardioblasts by exogenous cell therapy after myocardial infarction. EMBO Mol. Med. 6, 760-777 (2014
169. Dimmeler, S., Ding, S., Rando, T. A., & Trounson, A. Translational strategies and challenges in regenerative medicine. Nat. Med. 20, 814-821 (2014
170. Marban, E., Cho, H. C., & Cingolani, E. Taking the cells out of cell therapy. J. Am. Coll. Cardiol. 60, 1707-1708 (2012
171. Goldstein, J. L., & Brown, M. S. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161, 161-172 (2015
172. Patel, R., et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104, 317-324 (2001
173. Bauersachs, J., Galuppo, P., Fraccarollo, D., Christ, M., & Ertl, G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104, 982-985 (2001
174. Abulhul, E., et al. Long-Term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B type natriuretic peptide. Clin. Ther. 34, 91-100 (2012
175. Shiroshita-Takeshita, A., et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc. Res. 74, 75-84 (2007
176. Raghu, G., Johnson, W. C., Lockhart, D., & Mageto, Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. 159, 1061-1069 (1999
177. Tank, J., et al. Single-Target RNA interference for the blockade of multiple interacting proinflammatory and profibrotic pathways in cardiac fibroblasts. J. Mol. Cell. Cardiol. 66, 141-156 (2014
178. Szabo, Z., et al. Connective tissue growth factor inhibition attenuates left ventricular remodeling and dysfunction in pressure overload-induced heart failure. Hypertension 63, 1235-1240 (2014
179. Mirkovic, S., et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br. J. Pharmacol. 135, 961-968 (2002
180. Kagitani, S., et al. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J. Hypertens. 22, 1007-1015 (2004
181. Koitabashi, N., et al. Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J. Clin. Invest. 121, 2301-2312 (2011
182. Oyamada, S., Bianchi, C., Takai, S., Chu, L. M., & Sellke, F. W. Chymase inhibition reduces infarction and matrix metalloproteinase 9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J. Pharmacol. Exp. Ther. 339, 143-151 (2011
183. Kim, J., et al. Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies. J. Am. Coll. Cardiol. 48, 1378-1384 (2006
184. Hayashidani, S., et al. Anti-monocyte chemoattractant protein 1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 108, 2134-2140 (2003
185. Bujak, M., et al. Induction of the CXC chemokine interferon-γ-inducible protein 10 regulates the reparative response following myocardial infarction. Circ. Res. 105, 973-983 (2009
186. Rodriguez-Pascual, F., Busnadiego, O., & Gonzalez-Santamaria, J. The profibrotic role of endothelin 1: is the door still open for the treatment of fibrotic diseases? Life Sci. 118, 156-164 (2014
187. De Mello, W. C., & Specht, P. Chronic blockade of angiotensin II AT1 receptors increased cell to cell communication, reduced fibrosis and improved impulse propagation in the failing heart. J. Renin Angiotensin Aldosterone Syst. 7, 201-205 (2006
188. Shibasaki, Y., et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertens. Res. 28, 787-795 (2005
189. Daskalopoulos, E. P., Hermans, K. C., Janssen, B. J., & Matthijs Blankesteijn, W. Targeting the Wnt/frizzled signaling pathway after myocardial infarction: a new tool in the therapeutic toolbox? Trends Cardiovasc. Med. 23, 121-127 (2013
190. He, W., et al. Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc. Natl Acad. Sci. USA 107, 21110-21115 (2010
191. Luo, K., et al. The Ski oncoprotein interacts with the Smad proteins to repress TGFβ signaling. Genes Dev. 13, 2196-2206 (1999
192. Cunnington, R. H., et al. Antifibrotic properties of c Ski and its regulation of cardiac myofibroblast phenotype and contractility. Am. J. Physiol. Cell Physiol. 300, C176-C186 (2011
193. Espira, L., et al. The basic helix-loop-helix transcription factor scleraxis regulates fibroblast collagen synthesis. J. Mol. Cell. Cardiol. 47, 188-195 (2009
194. Balasubramanian, S., et al. β3 integrin in cardiac fibroblast is critical for extracellular matrix accumulation during pressure overload hypertrophy in mouse. PLoS ONE 7, e45076 (2012
195. Shivshankar, P., et al. Caveolin 1 deletion exacerbates cardiac interstitial fibrosis by promoting M2 macrophage activation in mice after myocardial infarction. J. Mol. Cell. Cardiol. 76, 84-93 (2014
196. Yi, S. L., Liu, X. J., Zhong, J. Q., & Zhang, Y. Role of caveolin 1 in atrial fibrillation as an anti-fibrotic signaling molecule in human atrial fibroblasts. PLoS ONE 9, e85144 (2014
197. Cunnington, R. H., Nazari, M., & Dixon, I. M. c Ski, Smurf2, and Arkadia as regulators of TGF-β signaling: new targets for managing myofibroblast function and cardiac fibrosis. Can. J. Physiol. Pharmacol. 87, 764-772 (2009
198. Czubryt, M. P. Common threads in cardiac fibrosis, infarct scar formation, and wound healing. Fibrogen. Tissue Repair 5, 19 (2012
199. Tourkina, E., et al. Antifibrotic properties of caveolin 1 scaffolding domain in vitro and in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L843-L861 (2008
200. Varr, B. C., & Maurer, M. S. Emerging role of serelaxin in the therapeutic armamentarium for heart failure. Curr. Atheroscler. Rep. 16, 447 (2014
201. Neverova, N., & Teerlink, J. R. Serelaxin: a potential new drug for the treatment of acute heart failure. Expert Opin. Investig. Drugs 23, 1017-1026 (2014
202. Tietjens, J., & Teerlink, J. R. Serelaxin and acute heart failure. Heart 102, 95-99 (2016
203. Squecco, R., et al. Inhibitory effects of relaxin on cardiac fibroblast-To myofibroblast transition: an electrophysiological study. Exp. Physiol. 100, 652-666 (2015
204. Sassoli, C., et al. Relaxin prevents cardiac fibroblast-myofibroblast transition via notch 1 mediated inhibition of TGF-β/Smad3 signaling. PLoS ONE 8, e63896 (2013
205. Small, E. M., Frost, R. J., & Olson, E. N. MicroRNAs add a new dimension to cardiovascular disease. Circulation 121, 1022-1032 (2010
206. Thum, T. MicroRNA therapeutics in cardiovascular medicine. EMBO Mol. Med. 4, 3-14 (2012
207. van Rooij, E., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR 29 in cardiac fibrosis. Proc. Natl Acad. Sci. USA 105, 13027-13032 (2008
208. Thum, T., et al. MicroRNA 21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984 (2008
209. Cardin, S., et al. Role for microRNA 21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ. Arrhythm. Electrophysiol. 5, 1027-1035 (2012
210. Patrick, D. M., et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA 21 in mice. J. Clin. Invest. 120, 3912-3916 (2010
211. US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02136862 (2016
212. Boon, R. A., & Dimmeler, S. MicroRNAs in myocardial infarction. Nat. Rev. Cardiol. 12, 135-142 (2015
213. Boon, R. A., et al. MicroRNA 34a regulates cardiac ageing and function. Nature 495, 107-110 (2013
214. Bang, C., et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J. Clin. Invest. 124, 2136-2146 (2014
215. Takeda, N., et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J. Clin. Invest. 120, 254-265 (2010
216. Burstein, B., Libby, E., Calderone, A., & Nattel, S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 117, 1630-1641 (2008).
217. Chatelier, A., et al. A distinct de novo expression of Nav1.5 sodium channels in human atrial fibroblasts differentiated into myofibroblasts. J. Physiol. 590, 4307-4319 (2012
218. Nakajima, H., et al. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-β1 transgene in the heart. Circ. Res. 86, 571-579 (2000
219. Verheule, S., et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF β1. Circ. Res. 94, 1458-1465 (2004
220. Wright, M., & Narayan, S. M. Ablation of atrial fibrillation. Trends Cardiovasc. Med. 25, 409-419 (2015
221. Moore, J. P. Arrhythmia management for the adult patient with congenital heart disease: an update and analytical review. Minerva Pediatr. 66, 415-439 (2014
222. Rog-Zielinska, E. A., Norris, R. A., Kohl, P., & Markwald, R. The living scar-cardiac fibroblasts and the injured heart. Trends Mol. Med. 22, 99-114 (2016
223. Rouillard, A. D., & Holmes, J. W. Coupled agent-based and finite-element models for predicting scar structure following myocardial infarction. Prog. Biophys. Mol. Biol. 115, 235-243 (2014
224. Koomalsingh, K. J., et al. Optimized local infarct restraint improves left ventricular function and limits remodeling. Ann. Thorac. Surg. 95, 155-162 (2013
225. Fomovsky, G. M., Clark, S. A., Parker, K. M., Ailawadi, G., & Holmes, J. W. Anisotropic reinforcement of acute anteroapical infarcts improves pump function. Circ. Heart Fail. 5, 515-522 (2012
226. Christman, K. L., Fok, H. H., Sievers, R. E., Fang, Q., & Lee, R. J. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng. 10, 403-409 (2004
227. Ifkovits, J. L., et al. Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model. Proc. Natl Acad. Sci. USA 107, 11507-11512 (2010
228. Rane, A. A., & Christman, K. L. Biomaterials for the treatment of myocardial infarction: a 5 year update. J. Am. Coll. Cardiol. 58, 2615-2629 (2011
229. Voorhees, A. P., et al. Building a better infarct: modulation of collagen cross-linking to increase infarct stiffness and reduce left ventricular dilation post-myocardial infarction. J. Mol. Cell. Cardiol. 85, 229-239 (2015
230. Purcell, B. P., et al. Injectable and bioresponsive hydrogels for on demand matrix metalloproteinase inhibition. Nat. Mater. 13, 653-661 (2014
231. Eckhouse, S. R., et al. Local hydrogel release of recombinant TIMP 3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Sci. Transl. Med. 6, 223ra21 (2014
232. Chung, E. S., et al. Effect of peri-infarct pacing early after myocardial infarction: results of the prevention of myocardial enlargement and dilatation post myocardial infarction study. Circ. Heart Fail. 3, 650-658 (2010
233. Hu, N., Yost, H. J., & Clark, E. B. Cardiac morphology and blood pressure in the adult zebrafish. Anat. Rec. 264, 1-12 (2001
234. Shimazaki, M., et al. Periostin is essential for cardiac healing after acute myocardial infarction. J. Exp. Med. 205, 295-303 (2008
235. Moldovan, N. I., et al. Reoxygenation-derived toxic reactive oxygen/nitrogen species modulate the contribution of bone marrow progenitor cells to remodeling after myocardial infarction. J. Am. Heart Assoc. 3, e000471 (2014
236. Norris, R. A., Gourdie, R. G., O'Quinn, M. P., & Markwald, R. R. Periostin inhibitory compositions for myocardial regeneration, methods of delivery, and methods of using same. US Patent US20100291188 A1 (2008
237. Bramwell, B. A. Case of heart-block, with fibrous degeneration and partial obliteration of the bundle of His. Br. Med. J. 1, 995-996 (1909
238. Kohl, P. Structural and functional recoupling of atrial and ventricular myocardium: new conduits for electrical flow. J. Am. Coll. Cardiol. 64, 2586-2588 (2014
239. Goshima, K. Synchronized beating of and electrotonic transmission between myocardial cells mediated by heterotypic strain cells in monolayer culture. Exp. Cell Res. 58, 420-426 (1969
240. Gaudesius, G., Miragoli, M., Thomas, S. P., & Rohr, S. Coupling of cardiac electrical activity over extended distances by fibroblasts of cardiac origin. Circ. Res. 93, 421-428 (2003
241. Lefroy, D. C., et al. Recipient-To donor atrioatrial conduction after orthotopic heart transplantation: surface electrocardiographic features and estimated prevalence. Am. J. Cardiol. 82, 444-450 (1998
242. Hager, A., et al. Congenital and surgically acquired Wolff-Parkinson-White syndrome in patients with tricuspid atresia. J. Thorac. Cardiovasc. Surg. 130, 48-53 (2005
243. Camelliti, P., Borg, T. K., & Kohl, P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 65, 40-51 (2005
244. Goldsmith, E. C., et al.organization of fibroblasts in the heart. Dev. Dyn. 230, 787-794 (2004
245. Rother, J., et al. Crosstalk of cardiomyocytes and fibroblasts in co cultures. Open Biol. 5, 150038 (2015
246. Kohl, P., & Camelliti, P. Fibroblast-myocyte connections in the heart. Heart Rhythm 9, 461-464 (2012
247. He, K., et al. Long-distance intercellular connectivity between cardiomyocytes and cardiofibroblasts mediated by membrane nanotubes. Cardiovasc. Res. 92, 39-47 (2011
248. Veeraraghavan, R., et al. Sodium channels in the Cx43 gap junction perinexus may constitute a cardiac ephapse: an experimental and modeling study. Pflugers Arch. 467, 2093-2105 (2015
249. Rhett, J. M., Veeraraghavan, R., Poelzing, S., & Gourdie, R. G. The perinexus: sign-post on the path to a new model of cardiac conduction? Trends Cardiovasc. Med. 23, 222-228 (2013
250. Kohl, P. Heterogeneous cell coupling in the heart: an electrophysiological role for fibroblasts. Circ. Res. 93, 381-383 (2003
251. Kohl, P., & Noble, D. Mechanosensitive connective tissue: potential influence on heart rhythm. Cardiovasc. Res. 32, 62-68 (1996
252. MacCannell, K. A., et al. A mathematical model of electrotonic interactions between ventricular myocytes and fibroblasts. Biophys. J. 92, 4121-4132 (2007
253. Nguyen, T. P., Qu, Z., & Weiss, J. N. Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. J. Mol. Cell. Cardiol. 70, 83-91 (2014
254. Camelliti, P., Devlin, G. P., Matthews, K. G., Kohl, P., & Green, C. R. Spatially and temporally distinct expression of fibroblast connexins after sheep ventricular infarction. Cardiovasc. Res. 62, 415-425 (2004
255. Thodeti, C. K., Paruchuri, S., & Meszaros, J. G. A TRP to cardiac fibroblast differentiation. Channels (Austin) 7, 211-214 (2013
256. Benamer, N., et al. Fibroblast KATP currents modulate myocyte electrophysiology in infarcted hearts. Am. J. Physiol. Heart Circ. Physiol. 304, H1231-H1239 (2013
257. Jacquemet, V., & Henriquez, C. S. Loading effect of fibroblast-myocyte coupling on resting potential, impulse propagation, and repolarization: insights from a microstructure model. Am. J. Physiol. Heart Circ. Physiol. 294, H2040-H2052 (2008
258. Sachse, F. B., Moreno, A. P., & Abildskov, J. A. Electrophysiological modeling of fibroblasts and their interaction with myocytes. Ann. Biomed. Eng. 36, 41-56 (2008
259. Maleckar, M. M., Greenstein, J. L., Giles, W. R., & Trayanova, N. A. Electrotonic coupling between human atrial myocytes and fibroblasts alters myocyte excitability and repolarization. Biophys. J. 97, 2179-2190 (2009
260. Xie, Y., et al. Effects of fibroblast-myocyte coupling on cardiac conduction and vulnerability to reentry: a computational study. Heart Rhythm 6, 1641-1649 (2009
261. Rutherford, S. L., Trew, M. L., Sands, G. B., LeGrice, I. J., & Smaill, B. H. High-resolution 3 dimensional reconstruction of the infarct border zone: impact of structural remodeling on electrical activation. Circ. Res. 111, 301-311 (2012
262. Ashihara, T., et al. The role of fibroblasts in complex fractionated electrograms during persistent/permanent atrial fibrillation: implications for electrogram-based catheter ablation. Circ. Res. 110, 275-284 (2012
263. Gonzales, M. J., Vincent, K. P., Rappel, W. J., Narayan, S. M., & McCulloch, A. D. Structural contributions to fibrillatory rotors in a patient-derived computational model of the atria. Europace 16 (Suppl 4.), iv3-iv10 (2014
264. McDowell, K. S., et al. Virtual electrophysiological study of atrial fibrillation in fibrotic remodeling. PLoS ONE 10, e0117110 (2015
265. Walker, N. L., Burton, F. L., Kettlewell, S., Smith, G. L., & Cobbe, S. M. Mapping of epicardial activation in a rabbit model of chronic myocardial infarction. J. Cardiovasc. Electrophysiol. 18, 862-868 (2007
266. Ripplinger, C. M., Lou, Q., Li, W., Hadley, J., & Efimov, I. R. Panoramic imaging reveals basic mechanisms of induction and termination of ventricular tachycardia in rabbit heart with chronic infarction: implications for low-voltage cardioversion. Heart Rhythm 6, 87-97 (2009
267. Saba, S., et al. Prevention of adverse electrical and mechanical remodeling with biventricular pacing in a rabbit model of myocardial infarction. Heart Rhythm 5, 124-130 (2008
268. Mahoney, V. Connexin 43 Mediates Electrotonic Conduction Across Non-Myocyte Lesions in the Intact Heart. Thesis, New York Univ. (2015
269. Quinn, T. A., et al. Cell-specific expression of voltage-sensitive protein confirms cardiac myocyte to non-myocyte electrotonic coupling in healed murine infarct border tissue. Circulation 130, A11749 (2014
270. Roell, W., et al. Engraftment of connexin 43 expressing cells prevents post-infarct arrhythmia. Nature 450, 819-824 (2007
271. O'Quinn, M. P., Palatinus, J. A., Harris, B. S., & Hewett, K. W., & Gourdie, R. G. A peptide mimetic of the connexin43 carboxyl-Terminus reduces gap junction remodeling and induced arrhythmia following ventricular injury. Circ. Res. 108, 704-715 (2011
272. Choi, Y. H., et al. Cardiac conduction through engineered tissue. Am. J. Pathol. 169, 72-85 (2006
273. Pratola, C., Baldo, E., Notarstefano, P., Toselli, T., & Ferrari, R. Radiofrequency ablation of atrial fibrillation: Is the persistence of all intraprocedural targets necessary for long-Term maintenance of sinus rhythm? Circulation 117, 136-143 (2008
274. Yankelson, L., et al. Cell therapy for modification of the myocardial electrophysiological substrate. Circulation 117, 720-731 (2008
275. Anderson, D. M., et al. A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell 160, 595-606 (2015
276. Smyth, J., W., & Shaw, R. M. Autoregulation of connexin43 gap junction formation by internally translated isoforms. Cell Rep. 5, 611-618 (2013
277. Ul Hussain, M., et al. Internal ribosomal entry site (IRES) activity generates endogenous carboxyl-Terminal domains of Cx43 and is responsive to hypoxic conditions. J. Biol. Chem. 289, 20979-20990 (2014
278. Lindsey, M. L., et al. Matrix metalloproteinase 7 affects connexin 43 levels, electrical conduction, and survival after myocardial infarction. Circulation 113, 2919-2928 (2006
279. Soares, A. R., et al. Gap junctional protein Cx43 is involved in the communication between extracellular vesicles and mammalian cells. Sci. Rep. 5, 13243 (2015
280. Lindsey, M. L., et al. Transformative impact of proteomics on cardiovascular health and disease: a scientific statement from the American Heart Association. Circulation 132, 852-872 (2015
281. Markwald, R. R., Fitzharris, T. P., & Smith, W. N. Sturctural analysis of endocardial cytodifferentiation. Dev. Biol. 42, 160-180 (1975
282. Rook, M. B., Jongsma, H. J., & de Jonge, B. Single channel currents of homo-And heterologous gap junctions between cardiac fibroblasts and myocytes. Pflugers Arch. 414, 95-98 (1989
283. Potts, J. D., & Runyan, R. B. Epithelial-mesenchymal cell transformation in the embryonic heart can be mediated, in part, by transforming growth factor β. Dev. Biol. 134, 392-401 (1989
284. Long, C. S., Henrich, C. J., & Simpson, P. C. A growth factor for cardiac myocytes is produced by cardiac nonmyocytes. Cell Regul. 2, 1081-1095 (1991
285. Kohl, P., Kamkin, A. G., Kiseleva, I. S., & Noble, D. Mechanosensitive fibroblasts in the sino-Atrial node region of rat heart: interaction with cardiomyocytes and possible role. Exp. Physiol. 79, 943-956 (1994
286. Morabito, C. J., Dettman, R. W., Kattan, J., Collier, J. M., & Bristow, J. Positive and negative regulation of epicardial-mesenchymal transformation during avian heart development. Dev. Biol. 234, 204-215 (2001
287. Assmus, B., et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106, 3009-3017 (2002
288. Perin, E. C., et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107, 2294-2302 (2003
289. Visconti, R. P., et al. An in vivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve interstitial cells. Circ. Res. 98, 690-696 (2006
290. Van de Werf, F. The history of coronary reperfusion. Eur. Heart J. 35, 2510-2515 (2014
291. Zannad, F., Alla, F., Dousset, B., Perez, A., & Pitt, B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation 102, 2700-2706 (2000
292. Singh, A. D., Amit, S., Kumar, O. S., Rajan, M., & Mukesh, N. Cardioprotective effects of bosentan, a mixed endothelin type A and B receptor antagonist, during myocardial ischaemia and reperfusion in rats. Basic Clin. Pharmacol. Toxicol. 98, 604-610 (2006
293. Klapholz, M. β-blocker use for the stages of heart failure. Mayo Clin. Proc. 84, 718-729 (2009
294. Siddesha, J. M., et al. Acetylsalicylic acid inhibits IL 18-induced cardiac fibroblast migration through the induction of RECK. J. Cell. Physiol. 229, 845-855 (2014
295. Mughal, R. S., et al. Peroxisome proliferator-Activated receptor γ-independent effects of thiazolidinediones on human cardiac myofibroblast function. Clin. Exp. Pharmacol. Physiol. 36, 478-486 (2009
296. Peterson, J. T. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 69, 677-687 (2006
297. Liao, C. H., et al. Cardiac mast cells cause atrial fibrillation through PDGF A mediated fibrosis in pressure-overloaded mouse hearts. J. Clin. Invest. 120, 242-253 (2010
298. Levick, S. P., et al. Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension 53, 1041-1047 (2009
299. Braunwald, E. The ten advances that have defined modern cardiology. Trends Cardiovasc. Med. 24, 179-183 (2014
300. Jaquet, K., et al. Reduction of myocardial scar size after implantation of mesenchymal stem cells in rats: what is the mechanism? Stem Cells Dev. 14, 299-309 (2005
301. Chen, L., Qin, F., Ge, M., Shu, Q., & Xu, J. Application of adipose-derived stem cells in heart disease. J. Cardiovasc. Transl Res. 7, 651-663 (2014
302. Heusch, G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ. Res. 116, 674-699 (2015
303. Qian, L., & Srivastava, D. Direct cardiac reprogramming: from developmental biology to cardiac regeneration. Circ. Res. 113, 915-921 (2013
304. Ye, L., Zimmermann, W. H., Garry, D. J., & Zhang, J. Patching the heart: cardiac repair from within and outside. Circ. Res. 113, 922-932 (2013
305. Bonauer, A., et al. MicroRNA 92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324, 1710-1713 (2009
306. Gurman, P., et al. Recombinant tissue plasminogen activators (rtPA): a review. Clin. Pharmacol. Ther. 97, 274-285 (2015
307. Shuros, A. C., et al. Ventricular preexcitation modulates strain and attenuates cardiac remodeling in a swine model of myocardial infarction. Circulation 116, 1162-1169 (2007
308. Bugyei-Twum, A., et al. High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovasc. Diabetol. 13, 89 (2014